Home > Specialists > Cardiovascular Surgery > Dr. Wenxing Peng (彭文星)

Specialty & Clinical Focus:
Cardiovascular clinical pharmacist at Beijing Anzhen Hospital in Beijing, with a focus on post-cardiac surgery medication therapy, anticoagulant and antiplatelet management, complex combination drug therapy, and cardiovascular pharmacotherapy for hypertension, severe heart disease, diabetes, and cerebrovascular conditions.
Professional Title & Qualifications:
Associate Chief Pharmacist
Hospital & Department:
Beijing Anzhen Hospital – Department of Aortic Surgery Center
(address: No. 2 Anzhen Road, Chaoyang District, Beijing, 100029)
Dr. Wenxing Peng (彭文星) - Clinical Pharmacist
Personal Biography
Dr. Wenxing Peng is an Associate Chief Pharmacist at the Aortic Surgery Center of Beijing Anzhen Hospital, Capital Medical University, with a clinical focus on post-cardiac surgery medication therapy, anticoagulant drug management and comprehensive cardiovascular pharmacotherapy.
Her work includes complex combination drug therapy, adverse drug reaction risk review and drug-interaction management for patients with hypertension, severe heart disease, diabetes and cerebrovascular conditions. Her academic background includes more than 40 publications in domestic and international medical journals and participation in national and provincial/ministerial-level cardiovascular pharmacy research projects.
Why Choose Dr. Wenxing Peng?
For patients preparing for complex cardiovascular treatment or aortic surgery, medication planning can be a key part of the overall care pathway. Dr. Wenxing Peng’s work at Beijing Anzhen Hospital focuses on cardiovascular pharmacotherapy, including anticoagulant and antiplatelet management, combination drug therapy, adverse-reaction prevention and drug-interaction review.
For international patients, a remote specialist-review request can help organize medication history, current prescriptions, previous procedures and specific questions before travel is considered. Dr. Peng’s cardiovascular pharmacy background is especially relevant for patients seeking specialist input on post-cardiac surgery medication strategy and complex cardiovascular drug management.
Pre-Travel Case Review & Specialist Liaison
Evaluate Your Cardiac Medication Strategy Before You Travel.
If you are uncertain about your current cardiovascular medication plan or preparing for a major cardiac procedure, MedBridgeNZ can coordinate pre-travel case preparation and remote specialist-review request communication with Dr. Wenxing Peng’s pathway where available.
Our medical concierge team helps organize your medical records, medication lists and key questions, coordinates translation support, and manages client-authorized document transfer and appointment communication. The relevant third-party hospital or specialist office will review submitted records for appointment triage or preliminary case-screening where available, helping you clarify administrative and travel feasibility before considering an in-person pathway in Beijing.
Disclaimer: MedBridgeNZ is a medical concierge provider serving a global client base. We assist with logistical coordination and facilitate access to healthcare professionals. MedBridgeNZ does not provide medical advice, diagnoses, or treatments.Any clinical feedback, treatment planning or suitability discussion remains with the relevant hospital or licensed specialist.
Secure a Remote Case Review with
Dr. Wenxing Peng
Areas of Expertise
Complex combination drug therapy management
Cardiovascular disease pharmacology
Pharmacological management for hypertension, heart disease, diabetes, and cerebrovascular conditions
Precision management of anticoagulants and antiplatelet drugs
Post-cardiac surgery medication strategy
Prevention and management of adverse drug reactions and drug interactions
Verified Client Satisfaction Metrics
⭐⭐⭐⭐⭐ 5.0/5.0 Overall Rating
* Treatment Pathway Satisfaction:
5.0/5.0
* Communication & Professionalism:
5.0/5.0
* High demand: Chosen online for specialist liaison and case reviews by over:
900 clients
(Source: These third-party platform indicators are provided for general reference only. They may change over time and should not be interpreted as a guarantee of diagnosis, treatment suitability, appointment availability, or individual clinical outcome.)
Work Experience
Associate Chief Pharmacist, Aortic Surgery Center, Beijing Anzhen Hospital, Capital Medical University (Current)
Education & Training
Awards & Honors
Academic & Professional Memberships
Youth Committee Member, Cardiovascular Pharmacy Branch, Chinese Society of Cardiothoracic and Vascular Anesthesiology
Committee Member, Metabolic Cardiovascular Specialty Committee, Beijing Endocrine and Metabolic Diseases Society
Committee Member, National Pharmacy Expert Group, Expert Volunteer Committee of Integrated Traditional Chinese and Western Medicine
Research & Publications
Published over 40 research papers in prominent domestic and international medical journals.
Hosted and participated in 5 national or provincial/ministerial-level scientific research projects.
Participated in the compilation and editing of 7 professional medical textbooks and monographs.
Selected Peer-Reviewed Publications
Below is a selection of Dr. Peng's peer-reviewed publications related to cardiovascular pharmacotherapy and perioperative medication management:
Clinical Outcomes of Individualized Antiplatelet Therapy Based on Platelet Function Test in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Peng W, Zhang Y, Lin B, Lin Y. J Cardiovasc Pharmacol. 2023 Apr 1;81(4):270-279. doi: 10.1097/FJC.0000000000001393. PMID: 36651931.
Anticoagulation strategies in patients with extracorporeal membrane oxygenation: A network meta-analysis and systematic review. Chen J, Chen G, Zhao W, Peng W. Pharmacotherapy. 2023 Oct;43(10):1084-1093. doi: 10.1002/phar.2859. Epub 2023 Aug 11. PMID: 37538041.
Metformin use is associated with reduced acute kidney injury following coronary artery bypass grafting in patients with type 2 diabetes: An inverse probability of treatment weighting analysis. Peng W, Yang B, Qiao H, Liu Y, Lin Y. Pharmacotherapy. 2023 Aug;43(8):778-786. doi: 10.1002/phar.2827. Epub 2023 Jun 1. PMID: 37199291.
*The doctor’s information is sourced from the hospital’s official website or provided directly by the doctor. Due to update cycles, there may be occasional delays in reflecting the most recent changes.
Frequently Asked Questions (FAQs)
How can I request remote specialist-review coordination with Dr. Wenxing Peng from outside China?
International patients can contact MedBridgeNZ to request administrative coordination for a remote specialist-review pathway with Dr. Wenxing Peng where available. With your authorization, MedBridgeNZ helps prepare medical records and medication lists, coordinate translation support, transfer documents to the relevant third-party hospital or specialist office, and support appointment communication so medication-related questions can be reviewed through the appropriate pathway.
What type of medication questions may be relevant for Dr. Peng’s cardiovascular pharmacy focus?
Dr. Peng’s listed clinical focus may be relevant for patients with post-cardiac surgery medication needs, anticoagulant or antiplatelet management, complex combination drug therapy, adverse drug reaction concerns, or drug-interaction questions related to hypertension, severe heart disease, diabetes or cerebrovascular conditions. The appropriateness of any specialist pathway depends on the records and the third-party specialist office’s triage process.
Does MedBridgeNZ provide medical advice, diagnosis, treatment or prescriptions?
No. MedBridgeNZ is a medical concierge and logistics coordination provider. We do not provide medical advice, diagnosis, treatment, prescriptions or clinical decision-making. Our role is to coordinate records preparation, translation support, client-authorized document transfer, appointment communication and travel logistics for independent specialist-care pathways in China.
What happens if further in-person care in Beijing is considered after record review?
MedBridgeNZ can support appointment request communication with Beijing Anzhen Hospital where available and coordinate non-clinical travel logistics such as medical invitation or visa-document coordination support, travel planning, accommodation communication, translation coordination and non-clinical bilingual administrative support for hospital visits. Hospital acceptance, appointment timing and clinical decisions remain with the relevant hospital or licensed specialist.
Flexible Ways to Connect with the Specialist
We understand that every client’s situation is unique. Beyond the Remote Written Review, we offer a range of flexible ways to access specialist insights:
-
Remote Video Liaison: For a more personal interaction, we can arrange a live video session, allowing you to discuss your case directly with the specialist with the help of our professional medical translators.
-
On-Site Proxy Liaison: If you cannot travel, our dedicated bilingual team can visit the hospital in person on your behalf. We will present your translated medical records to the specialist, facilitate your inquiries, and provide you with a comprehensive translated report of the doctor’s findings.
-
In-Person Appointment Booking: If you are planning to travel to China for treatment, we manage the complex hospital registration and appointment process, ensuring you have confirmed access to your chosen specialist upon arrival.
How MedBridgeNZ Helps You:
MedBridgeNZ is a medical concierge and logistics coordination provider for international patients considering specialist-care pathways in China. For Dr. Wenxing Peng’s cardiovascular pharmacy pathway, we help with appointment request coordination, medical-record and medication-list preparation, translation coordination, client-authorized document transfer, medical invitation or visa-document coordination support, travel planning and non-clinical bilingual administrative support. MedBridgeNZ does not provide medical advice, diagnosis or treatment, and third-party medical or travel costs remain separate unless expressly stated in writing.
